PTPI - EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC' Petros Pharma President Says | Benzinga
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men’s health therapeutics.
In an interview with Benzinga, Fady Boctor, the President and Chief Commercial Officer of Petros Pharmaceuticals, said the company aims to expand access of key prescription pharmaceuticals as over-the-counter (OTC) treatment options.
Boctor added that Petros is a pure play in the Rx-to-OTC self-care market, focused on bringing its current lead erectile dysfunction (ED) therapeutic OTC while developing a pathway that would take future therapeutics OTC as well.
“Rx-to-OTC is emerging as a substantial self-care industry among pharmaceutical companies. According to FMI’s Rx-to-OTC Switches Market, the Rx-to-OTC switch market is projected to reach $66.5 billion by 2033,” Boctor told Benzinga.
Here’s a summary of the Q&A:
- Benzinga: Can you tell us more about your company and products and how you differentiate yourself from competitors?
- Fady Boctor: “We have a broad network and deep talent in the Rx-to-OTC switch marketplace. We have decades of experience in the Rx, switch, and FDA regulatory landscape. This enables us to leverage industry best practices and meaningful familiarity ...